SOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 2,500 Shares

Key Points

• CEO Jurgi Camblong sold 2,500 shares on April 7 at an average price of $4.86 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 3,728,950 shares (a 0.07% reduction).
• SOPH stock traded at $4.89 (down ~0.3%) with a market cap of $334.6M, and the company reported a quarterly EPS of -$0.28 (missing estimates) while revenue of $21.71M slightly topped expectations.
• Analyst coverage is mixed—two Buys and one Sell—with a consensus rating of "Hold" and an average price target of $7.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 2,500 shares of the firm's stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $4.86, for a total value of $12,150.00. Following the completion of the transaction, the chief executive officer owned 3,728,950 shares in the company, valued at $18,122,697. This represents a 0.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Stock Down 0.3%

Shares of SOPH stock traded down $0.01 during trading hours on Wednesday, reaching $4.89. The company had a trading volume of 64,929 shares, compared to its average volume of 188,371. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The business has a fifty day simple moving average of $4.78 and a 200-day simple moving average of $4.68. The company has a market cap of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. On average, research analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SOPH has been the topic of a number of recent analyst reports. BTIG Research reiterated a "buy" rating and set a $7.00 price target on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Finally, Guggenheim lifted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, SOPHiA GENETICS presently has an average rating of "Hold" and a consensus price target of $7.00.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Federated Hermes Inc. lifted its holdings in SOPHiA GENETICS by 16.4% during the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock worth $682,000 after acquiring an additional 31,000 shares during the period. Akre Capital Management LLC lifted its holdings in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter worth $6,708,000. Finally, Savvy Advisors Inc. bought a new stake in SOPHiA GENETICS during the third quarter worth $48,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.